The goal of the CRC 1160
The Collaborative Research Center (CRC) 1160. “Immune-mediated pathology as a consequence of impaired immune reactions (IMPATH)” is a research consortium of clinical and basic immunologists exploring the basis of diseases mediated by the immune system.
The CRC sets out to challenge the traditional idea that an “overreaction” or “deviation“ of normal immune responses is pivotal to immune mediated pathology and that, consequently, immunosuppression is the appropriate therapeutic strategy for such disorders. Instead, the conceptual basis of the CRC is the idea that impaired immune reactions constitute a major prerequisite for immunopathology. This is what we call the “IMPATH paradox”. This paradox implies that immune reconstitution and/or immune stimulation rather than immunosuppression represent appropriate therapeutic principles for these forms of immunopathology.
News
Publications
Mann J, Runge S, Schell C, Gräwe K, Thoulass G, Lao J, Ammann S, Grün S, König C, Berger SA, Hild B, Aichele P, Rosshart SP, Ehl S. 2024. The Microbiome Modifies Manifestations of Hemophagocytic Lymphohistiocytosis in Perforin-Deficient Mice. Eur J Immunol. 2024 Nov 16:e202451061. doi: 10.1002/eji.202451061.
Giesler S, Riemer R, Lowinus T, Zeiser R. 2024. Immune-mediated colitis after immune checkpoint inhibitor therapy. Trends Mol Med. 2024 Oct 29:S1471-4914(24)00266-1. doi: 10.1016/j.molmed.2024.09.009.
Vogele D, Wöhrle S, Saller BS, Fröhlich K, Barta BA, Cosenza-Contreras M, Groß O, Schilling O. 2024. Size exclusion chromatography based proteomic and degradomic profiling of inflammasome-activated, murine bone marrow-derived dendritic cells highlights complex retention and release of cleavage products. Mol Omics. 2024 Oct 28;20(9):595-610. doi: 10.1039/d4mo00163j.
Minguet S, Maus MV, Schamel WW. 2024. From TCR fundamental research to innovative chimeric antigen receptor design. Nat Rev Immunol. 2024 Oct 21. doi: 10.1038/s41577-024-01093-7.
Hofmann M, Thimme R, Schamel WW. 2024. PD-1 and LAG-3: synergistic fostering of T cell exhaustion. Signal Transduct Target Ther. 2024 Oct 18;9(1):291. doi: 10.1038/s41392-024-02000-1.
Contact
Scientific Manager/Administration
Dr. Heike Ufheil
Institute for Immunodeficiency,
Center for Chronic Immunodeficiency (CCI)
Medical Center – University of Freiburg
